SUDOSCAN in wild-type cardiac amyloidosis and AA amyloidosis – JFMA 2020

Share on facebook
Share on twitter
Share on linkedin

Multidisciplinary French speaking day of Amyloidosis – JFMA 2020

Last month, SUDOSCAN was presented at the virtual Multidisciplinary French speaking day of Amyloidosis. The congress gathered 300 participants with a large scientific program on the different amyloidosis types.

Amyloidosis is an acquired or hereditary rare disease due to amyloid protein deposits into organs. Several types have been reported including Transthyretine hereditary amyloidosis (hATTR amyloidosis or familial amyloidosis), wild-type cardiac amyloidosis, AA amyloidosis and AL amyloidosis.

During this congress, the utility of SUDOSCAN to detect autonomic peripheral neuropathy was demonstrated by two different teams in AA amyloidosis and wild-type cardiac amyloidosis. Regarding AA amyloidosis, S. Deshayes from Caen Hospital presented a study performed in the reference center for this disease (Tenon Hospital, Paris) on 32 patients with results comparable to studies published on AL amyloidosis and familial amyloidosis (a paper will be submitted soon, the study will be extended and SUDOSCAN will be included in the follow-up of patients with AA amyloidosis).
Regarding wild-type cardiac amyloidosis, M. Kharoubi from Henri Mondor University Hospital, Paris, Pr T. Damy’s team, has presented new results on screening autonomic neuropathy with SUDOSCAN in transthyretin wild-type cardiac amyloidosis (ATTRwt-CA). These results published recently in ESC Heart Failure Journal [1], demonstrated that SUDOSCAN feet measures were reduced in almost 50% of patients with ATTRwt-CA and was associated with a worse prognosis helping identify patients at higher risk for a poor outcome. 

These new findings in cardiac amyloidosis highlight the functional interest of SUDOSCAN in daily cardiology practice. SUDOSCAN testing could be completed by the cardiologists and would allow patients with ATTRwt-CA and poor electrochemical skin conductance to be triaged for consultation with a neurologist for further investigation, thus optimizing the management and monitoring of these patients.

Congress session presentation available below: 

[1] M. Kharoubi et al (T.Damy). Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis. ESC Heart Failure (2020). Article available here.

Impeto Medical

Impeto Medical

About Impeto Medical

Impeto Medical has developed a patented technology that assesses sudomotor function quickly and non-invasively. The results are a conductance, which expresses the health of the small nerve fibers innervating the sweat glands. The ease-of-use, quantitative, reproducible and sensitive results encourage its use to detect and follow the evolution of small fiber neuropathy.

Recent Posts

Subscribe to receive our scientific news

Name(Required)
Consent(Required)

Website dedicated
to health professionals

Scroll to Top